Magnesium salt of L-threonate

Plain-language summaryIntrigue 58 / 100

Magnesium L-threonate is a magnesium salt designed to penetrate the blood-brain barrier better than other magnesium forms. Developed by MIT researchers and marketed as Magtein for cognitive support. Clinical evidence is limited. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

48/100

Novel CNS-delivery magnesium salt with real but consortium-narrow evidence and modest cognitive signal

The story here starts with a real scientific observation. Guosong Liu’s group at MIT showed, in a 2010 paper in Neuron, that chronically elevating brain magnesium improves synaptic density and working memory in rodents, and that standard magnesium salts don’t reliably cross into the CNS in meaningful quantities. L-threonate complexation changed that. The rodent data was compelling enough that Magtein got licensed, commercialized, and into phase 2 trials before most researchers had finished reading the paper. That’s a faster bench-to-market arc than you usually see for a magnesium salt, and it tells you the mechanism hypothesis resonated with people who fund things.

Here’s the thing though: the mechanism itself is downstream of well-understood magnesium biology. NMDA receptor co-agonism, synaptic plasticity, long-term potentiation gating. None of that is new pharmacology. What’s interesting is the delivery problem being solved, not the endpoint being targeted. Magnesium’s CNS role is established; what’s genuinely novel is the claim that you can selectively elevate brain magnesium with a specific salt when others fail at the blood-brain interface. If that claim holds up under independent replication, it’s a legitimately useful research tool. If it doesn’t, it’s just an expensive magnesium supplement with good branding.

The evidence situation is real but limited. The Liu consortium drove the preclinical work heavily, and the phase 2 trials in mild cognitive impairment produced modest, consistent improvements on cognitive endpoint measures. “Modest and consistent” is better than “massive and irreproducible,” but it doesn’t make for a screaming research case. Outside the MIT-affiliated research chain, independent replication is thin. We haven’t seen the multi-center, higher-powered trials that would make this a serious clinical story. What we have is a coherent preclinical model, a plausible delivery mechanism, and early human signal that’s real but needs substantially more work.

From a bench perspective, it carries genuine probe value. If you’re studying CNS magnesium dynamics, having a form that preferentially elevates brain magnesium without the systemic confound that dominates standard oral Mg studies is actually useful. That’s not nothing. But the research community isn’t exactly rushing to build programs around it, and the single-consortium footprint on the key papers is a flag you shouldn’t ignore when evaluating the literature.

We’d call this worth watching but not worth leading with. It scores where it scores because the underlying idea is clever, the human signal is real if modest, and the CNS bioavailability story is meaningfully differentiated from generic mineral territory. But thats not the same as saying it belongs anywhere near the top tier. The evidence base is too narrow, the mechanism serves well-understood Mg biology rather than breaking new ground, and the Liu group’s outsized authorship share on the strongest papers makes independent verification genuinely difficult to assess.

Novelty: 45
Mechanism promise: 55
In-category differentiation: 55
Evidence quality: 40
Translational signal: 42
Research bench value: 48

Rationale Scores as novel-promising because the L-threonate complexation angle is genuinely differentiated from generic magnesium salts and the CNS bioavailability hypothesis is mechanistically coherent; held back by single-consortium evidence dominance and an endpoint mechanism (NMDA/synaptic plasticity) that is well-understood rather than frontier biology.

Magnesium salt of L-threonate

A proprietary magnesium salt (Magtein) with claimed superior CNS bioavailability for cognitive applications.

Abstract

Magnesium L-Threonate (Magtein; CAS 778571-57-6) is a proprietary magnesium salt developed at MIT by Guosong Liu’s group, complexing magnesium with two molecules of L-threonate (a vitamin C metabolite). The complex was designed for CNS delivery; rodent studies showed elevated brain magnesium levels and synaptic density improvements with chronic supplementation, distinguishing it from other magnesium salts which produce less reliable CNS magnesium elevation. Phase 2 trials in mild cognitive impairment have shown modest but consistent improvements in cognitive endpoint measures. Doses are typically 1 to 2 grams of the salt per day (providing 100 to 200 mg elemental magnesium). The compound is sold as Magtein-branded products and generic equivalents.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-167Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Magnesium salt of L-threonate

Magnesium L-Threonate

Abstract

Read the full monograph